Related Experiment Video
Updated: Dec 3, 2025
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
824
Mesalamine in the Initial Therapy of Ulcerative Colitis
1BIDMC, Division of Gastroenterology, 1011 - 200 Brookline Avenue, Boston, MA 02115, USA.
Gastroenterology Clinics of North America
|October 30, 2020
Summary
Mesalamine is a safe and effective first-line treatment for ulcerative colitis, particularly at higher doses. While generally well-tolerated, patient adherence to this inflammatory bowel disease therapy can be a challenge.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic intestinal inflammation disorder.
- Conventional therapies aim to induce and maintain remission in IBD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of mesalamine as a first-line therapy for ulcerative colitis.
- To determine optimal dosing strategies for mesalamine in achieving remission and preventing relapse.
Main Methods:
- Review of clinical trials investigating mesalamine in mild to moderate ulcerative colitis.
- Analysis of efficacy data regarding clinical and endoscopic remission rates.
- Assessment of safety profiles and adverse effects, including adherence and pregnancy considerations.
Main Results:
- Mesalamine is confirmed as effective and safe for mild to moderate ulcerative colitis.
- Doses exceeding 2.4 g/day show significantly higher remission rates and reduced relapse risk.
- Serious adverse effects are rare, though nonadherence is common. Mesalamine is safe in pregnancy, excluding specific formulations.
Conclusions:
- Mesalamine is a valuable first-line treatment for ulcerative colitis.
- Higher mesalamine dosages enhance therapeutic outcomes.
- Addressing patient adherence is crucial for optimizing mesalamine therapy in inflammatory bowel disease management.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
332
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
332
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
349
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
349
01:29Inflammatory Bowel Disease IV: Pharmacological Management
317
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
317
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
313
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
313
01:21Inflammatory Bowel Disease V: Surgical Management
325
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
325
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
528
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
528